NIH Renews Its Pharmacogenetics Research Network
Complete the form below to unlock access to ALL audio articles.
Continuing its support for studies on how genes affect responses to medications, the National Institutes of Health has announced that it anticipates spending $150 million over five years to renew its Pharmacogenetics Research Network (PGRN).
The research of this nationwide network of scientists will eventually help doctors tailor drug prescriptions to people's unique genetic make-ups.
Spearheaded by NIH's National Institute of General Medical Sciences and originally funded from 2000 to 2005, the PGRN's record of success includes discoveries about medications used for such serious diseases as cancer, heart disease, and asthma.
"By showing how our genes influence our responses to medicines, the PGRN is making critical advances that will maximize the benefits of treatment while minimizing adverse side effects," said NIH Director Elias A. Zerhouni, MD.
"This will ultimately improve patient outcomes and reduce health care costs," said NIH Director Elias A. Zerhouni, MD.
